Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset

Patrícia Figueiredo-Campos; Birte Blankenhaus; Catarina Mota; Andreia Gomes; Marta Serrano; Silvia Ariotti; Catarina Costa; Helena Nunes-Cabaço; António M. Mendes; Pedro Gaspar; M. Conceição Pereira-Santos; Fabiana Rodrigues; Jorge Condeço; M. Antonia Escoval; Matilde Santos; Mario Ramirez; José Melo-Cristino; J. Pedro Simas; Eugenia Vasconcelos; Ângela Afonso; Marc Veldhoen

doi:10.1002/eji.202048970

Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset

Patrícia Figueiredo-Campos
, Birte Blankenhaus
, Catarina Mota
, Andreia Gomes
, Marta Serrano
, Silvia Ariotti
, Catarina Costa
, Helena Nunes-Cabaço
, António M. Mendes
, Pedro Gaspar
, M. Conceição Pereira-Santos
, Fabiana Rodrigues
, Jorge Condeço
, M. Antonia Escoval
, Matilde Santos
, Mario Ramirez
, José Melo-Cristino
, J. Pedro Simas
, Eugenia Vasconcelos
, Ângela Afonso

Marc Veldhoen^*

^*Autor correspondente para este trabalho

Resultado de pesquisa › revisão de pares

167 Citações (Scopus)

30 Transferências (Pure)

Resumo

SARS-CoV-2 has emerged as a human pathogen, causing clinical signs, from fever to pneumonia—COVID-19—but may remain mild or asymptomatic. To understand the continuing spread of the virus, to detect those who are and were infected, and to follow the immune response longitudinally, reliable and robust assays for SARS-CoV-2 detection and immunological monitoring are needed. We quantified IgM, IgG, and IgA antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) or the Spike (S) protein over a period of 6 months following COVID-19 onset. We report the detailed setup to monitor the humoral immune response from over 300 COVID-19 hospital patients and healthcare workers, 2500 University staff, and 198 post-COVID-19 volunteers. Anti-SARS-CoV-2 antibody responses follow a classic pattern with a rapid increase within the first three weeks after symptoms. Although titres reduce subsequently, the ability to detect anti-SARS-CoV-2 IgG antibodies remained robust with confirmed neutralization activity for up to 6 months in a large proportion of previously virus-positive screened subjects. Our work provides detailed information for the assays used, facilitating further and longitudinal analysis of protective immunity to SARS-CoV-2. Importantly, it highlights a continued level of circulating neutralising antibodies in most people with confirmed SARS-CoV-2.

Idioma original	English
Páginas (de-até)	2025-2040
Número de páginas	16
Revista	European Journal of Immunology
Volume	50
Número de emissão	12
DOIs	https://doi.org/10.1002/eji.202048970
Estado da publicação	Publicado - dez. 2020

ODS da ONU

Este resultado contribui para o(s) seguinte(s) Objetivo(s) de Desenvolvimento Sustentável

ODS 3 Boa saúde e bem-estar

Acesso ao documento

10.1002/eji.202048970Licença:

27401061Final published version, 6,69 MBLicença:

http://hdl.handle.net/10400.14/32227Licença:

Outros arquivos e links

Link to publication in Scopus

CIIS: Centro de Investigação Interdisciplinar em Saúde
Barros, M. (PI), Rosa, N. (Investigador), Correia, M. J. (Investigador), Caldas, A. C. (Investigador), Amado, J. C. (Investigador), Figueiredo, A. S. (Investigador), Esteves, A. C. (Investigador), Mineiro, A. (Investigador), Abreu, A. M. (Investigador), Duarte, A. S. (Investigador), Almeida, S. F. (Investigador), Correia, A. (Investigador), Moura, A. (Investigador), Almeida, A. (Investigador), Araújo, B. (Investigador), Moura-Netto, C. (Investigador), Ferrito, C. (Investigador), Pais-Vieira, C. (Investigador), Festas, C. (Investigador), Marques-Vieira, C. (Investigador), Catré, D. (Investigador), Nunes, E. (Investigador), Jesus, É. (Investigador), Ribeiro, F. (Investigador), Rosário, F. (Investigador), Fernandes, G. (Investigador), Rato, J. R. (Bolseiro), Salgado, J. R. (Investigador), Neves-Amado, J. (Investigador), Amendoeira, J. (Investigador), Sá, L. (Investigador), Capelas, M. L. (Investigador), Vieira, M. M. (Investigador), Nunes, M. V. S. (Investigador), Cardoso, M. (Investigador), Veiga, N. J. (Investigador), Fonseca, P. (Investigador), Correia, P. N. (Investigador), Couto, P. (Investigador), Pontífice-Sousa, P. (Investigador), Ravasco, P. (Investigador), Carvalho, P. V. D. (Investigador), Alves, P. (Investigador), Melo, P. (Investigador), Silva, R. (Investigador), Canaipa, R. (Investigador), Noites, R. (Investigador), Rio, R. (Investigador), Almeida, S. (Investigador), Deodato, S. (Investigador), Caldeira, S. (Investigador), Silva, S. (Investigador), Borges, T. (Investigador), Silva, V. (Investigador), Charepe, Z. (Investigador), Rodrigues-Pires, F. (Voluntário), Veludo, F. (Investigador), Carmo, H. (Bolseiro), Romeiro, J. (Estudante), Melo, M. (Investigador), Braga, M. (Investigador), Amaral, T. (Investigador), Moreira, M. A. (Investigador), Guerra, N. (Estudante), Santos, P. (Investigador), Paço, S. (Estudante), Lynce, S. (Bolseiro), Miguel, S. (Estudante), Costa, T. (Investigador), Silva-Neves, V. (Investigador), Silva, A. (Investigador), Carvalho, A. R. (Investigador), Almeida, B. (Investigador), Figueiredo, C. (Investigador), Esteves, E. (Bolseiro), Araújo, F. M. (Investigador), Garcia, J. G. (Investigador), Santos, L. (Investigador), Santos, N. M. D. (Investigador), Lopes, P. (Investigador), Bornes, R. (Investigador), Silva, R. (Investigador), Costa, S. (Investigador), Silva, S. M. (Investigador), Marques, T. (Investigador), Almeida, A. (Investigador), Santos, M. (Bolseiro), Santos, P. (Investigador), Miguel, S. (Investigador), Mendes, K. (Investigador), Gomes, A. P. (Investigador), Henriques, J. M. P. (Investigador), Costa, H. (Investigador) & Ribeiro, P. (Investigador)
Fundação para a Ciência e a Tecnologia
1/01/20 → 31/12/24
Projeto

Citação

Figueiredo-Campos, P., Blankenhaus, B., Mota, C., Gomes, A., Serrano, M., Ariotti, S., Costa, C., Nunes-Cabaço, H., Mendes, A. M., Gaspar, P., Pereira-Santos, M. C., Rodrigues, F., Condeço, J., Escoval, M. A., Santos, M., Ramirez, M., Melo-Cristino, J., Simas, J. P., Vasconcelos, E., ... Veldhoen, M. (2020). Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. European Journal of Immunology, 50(12), 2025-2040. https://doi.org/10.1002/eji.202048970

@article{32eea1f1005e4425a8248939c1238c69,

title = "Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset",

abstract = "SARS-CoV-2 has emerged as a human pathogen, causing clinical signs, from fever to pneumonia—COVID-19—but may remain mild or asymptomatic. To understand the continuing spread of the virus, to detect those who are and were infected, and to follow the immune response longitudinally, reliable and robust assays for SARS-CoV-2 detection and immunological monitoring are needed. We quantified IgM, IgG, and IgA antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) or the Spike (S) protein over a period of 6 months following COVID-19 onset. We report the detailed setup to monitor the humoral immune response from over 300 COVID-19 hospital patients and healthcare workers, 2500 University staff, and 198 post-COVID-19 volunteers. Anti-SARS-CoV-2 antibody responses follow a classic pattern with a rapid increase within the first three weeks after symptoms. Although titres reduce subsequently, the ability to detect anti-SARS-CoV-2 IgG antibodies remained robust with confirmed neutralization activity for up to 6 months in a large proportion of previously virus-positive screened subjects. Our work provides detailed information for the assays used, facilitating further and longitudinal analysis of protective immunity to SARS-CoV-2. Importantly, it highlights a continued level of circulating neutralising antibodies in most people with confirmed SARS-CoV-2.",

keywords = "COVID-19, Neutralizing antibodies, SARS-CoV-2, Seroprevalence",

author = "Patr{\'i}cia Figueiredo-Campos and Birte Blankenhaus and Catarina Mota and Andreia Gomes and Marta Serrano and Silvia Ariotti and Catarina Costa and Helena Nunes-Caba{\c c}o and Mendes, \{Ant{\'o}nio M.\} and Pedro Gaspar and Pereira-Santos, \{M. Concei{\c c}{\~a}o\} and Fabiana Rodrigues and Jorge Conde{\c c}o and Escoval, \{M. Antonia\} and Matilde Santos and Mario Ramirez and Jos{\'e} Melo-Cristino and Simas, \{J. Pedro\} and Eugenia Vasconcelos and {\^A}ngela Afonso and Marc Veldhoen",

note = "Funding Information: We would like to acknowledge the generous sharing of the expression constructs by Drs Florian Krammer and Benhur Lee, Icahn School of Medicine at Mount Sinai, New York, USA (Development of SARS‐CoV‐2 reagents was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C), and the protein production by Drs Paula Alves, Pedro Cruz, and Rute Castro at Instituto de Biologia Experimental e Tecnol{\'o}gica (iBET) Oeiras, Portugal as part of the Serology4COVID consortium. Funding Information: We would like to thank all volunteers who helped with blood collections (AR Pires, A Ramalho‐dos‐Santos, A Biscaia‐Santos, F Ribeiro, S Caetano, P Napole{\~a}o, MJ Silva, P Alves, R Pedroso, P Corredeira, A Fri{\~a}es, M De Niz, I Bento, S Pereira, S Mensurado) and donors and patients for providing blood samples and cooperation to make this study possible. Serum samples were requested from Biobanco‐IMM, Lisbon Academic Medical Centre, Lisbon, Portugal. We like to acknowledge the funding from the European Union H2020 ERA project (No 667824 – EXCELLtoINNOV) and the Funda{\c c}{\~a}o para a Ci{\^e}ncia e a Tecnologia (FCT) to P.F‐C. (SFRH/BD/131605/2017), PTDC/MED‐IMU/28003/2017, and research4COVID19 (no. 231\_596873172, Generating SARS‐CoV2 seroconversion assay and no. 729, High‐throughput SARS‐CoV2 neutralizing antibodies assessment), with additional support by Sociedade Francisco Manuel dos Santos. Funding Information: We would like to thank all volunteers who helped with blood collections (AR Pires, A Ramalho-dos-Santos, A Biscaia-Santos, F Ribeiro, S Caetano, P Napole{\~a}o, MJ Silva, P Alves, R Pedroso, P Corredeira, A Fri{\~a}es, M De Niz, I Bento, S Pereira, S Mensurado) and donors and patients for providing blood samples and cooperation to make this study possible. Serum samples were requested from Biobanco-IMM, Lisbon Academic Medical Centre, Lisbon, Portugal. We like to acknowledge the funding from the European Union H2020 ERA project (No 667824 – EXCELLtoINNOV) and the Funda{\c c}{\~a}o para a Ci{\^e}ncia e a Tecnologia (FCT) to P.F-C. (SFRH/BD/131605/2017), PTDC/MED-IMU/28003/2017, and research4COVID19 (no. 231\_596873172, Generating SARS-CoV2 seroconversion assay and no. 729, High-throughput SARS-CoV2 neutralizing antibodies assessment), with additional support by Sociedade Francisco Manuel dos Santos. We would like to acknowledge the generous sharing of the expression constructs by Drs Florian Krammer and Benhur Lee, Icahn School of Medicine at Mount Sinai, New York, USA (Development of SARS-CoV-2 reagents was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C), and the protein production by Drs Paula Alves, Pedro Cruz, and Rute Castro at Instituto de Biologia Experimental e Tecnol{\'o}gica (iBET) Oeiras, Portugal as part of the Serology4COVID consortium. Publisher Copyright: {\textcopyright} 2020 The Authors. European Journal of Immunology published by Wiley-VCH GmbH",

year = "2020",

month = dec,

doi = "10.1002/eji.202048970",

language = "English",

volume = "50",

pages = "2025--2040",

journal = "European Journal of Immunology",

issn = "0014-2980",

publisher = "Wiley-VCH Verlag",

number = "12",

}

Figueiredo-Campos, P, Blankenhaus, B, Mota, C, Gomes, A, Serrano, M, Ariotti, S, Costa, C, Nunes-Cabaço, H, Mendes, AM, Gaspar, P, Pereira-Santos, MC, Rodrigues, F, Condeço, J, Escoval, MA, Santos, M, Ramirez, M, Melo-Cristino, J, Simas, JP, Vasconcelos, E, Afonso, Â & Veldhoen, M 2020, 'Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset', European Journal of Immunology, vol. 50, n.º 12, pp. 2025-2040. https://doi.org/10.1002/eji.202048970

TY - JOUR

T1 - Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset

AU - Figueiredo-Campos, Patrícia

AU - Blankenhaus, Birte

AU - Mota, Catarina

AU - Gomes, Andreia

AU - Serrano, Marta

AU - Ariotti, Silvia

AU - Costa, Catarina

AU - Nunes-Cabaço, Helena

AU - Mendes, António M.

AU - Gaspar, Pedro

AU - Pereira-Santos, M. Conceição

AU - Rodrigues, Fabiana

AU - Condeço, Jorge

AU - Escoval, M. Antonia

AU - Santos, Matilde

AU - Ramirez, Mario

AU - Melo-Cristino, José

AU - Simas, J. Pedro

AU - Vasconcelos, Eugenia

AU - Afonso, Ângela

AU - Veldhoen, Marc

N1 - Funding Information: We would like to acknowledge the generous sharing of the expression constructs by Drs Florian Krammer and Benhur Lee, Icahn School of Medicine at Mount Sinai, New York, USA (Development of SARS‐CoV‐2 reagents was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C), and the protein production by Drs Paula Alves, Pedro Cruz, and Rute Castro at Instituto de Biologia Experimental e Tecnológica (iBET) Oeiras, Portugal as part of the Serology4COVID consortium. Funding Information: We would like to thank all volunteers who helped with blood collections (AR Pires, A Ramalho‐dos‐Santos, A Biscaia‐Santos, F Ribeiro, S Caetano, P Napoleão, MJ Silva, P Alves, R Pedroso, P Corredeira, A Friães, M De Niz, I Bento, S Pereira, S Mensurado) and donors and patients for providing blood samples and cooperation to make this study possible. Serum samples were requested from Biobanco‐IMM, Lisbon Academic Medical Centre, Lisbon, Portugal. We like to acknowledge the funding from the European Union H2020 ERA project (No 667824 – EXCELLtoINNOV) and the Fundação para a Ciência e a Tecnologia (FCT) to P.F‐C. (SFRH/BD/131605/2017), PTDC/MED‐IMU/28003/2017, and research4COVID19 (no. 231_596873172, Generating SARS‐CoV2 seroconversion assay and no. 729, High‐throughput SARS‐CoV2 neutralizing antibodies assessment), with additional support by Sociedade Francisco Manuel dos Santos. Funding Information: We would like to thank all volunteers who helped with blood collections (AR Pires, A Ramalho-dos-Santos, A Biscaia-Santos, F Ribeiro, S Caetano, P Napoleão, MJ Silva, P Alves, R Pedroso, P Corredeira, A Friães, M De Niz, I Bento, S Pereira, S Mensurado) and donors and patients for providing blood samples and cooperation to make this study possible. Serum samples were requested from Biobanco-IMM, Lisbon Academic Medical Centre, Lisbon, Portugal. We like to acknowledge the funding from the European Union H2020 ERA project (No 667824 – EXCELLtoINNOV) and the Fundação para a Ciência e a Tecnologia (FCT) to P.F-C. (SFRH/BD/131605/2017), PTDC/MED-IMU/28003/2017, and research4COVID19 (no. 231_596873172, Generating SARS-CoV2 seroconversion assay and no. 729, High-throughput SARS-CoV2 neutralizing antibodies assessment), with additional support by Sociedade Francisco Manuel dos Santos. We would like to acknowledge the generous sharing of the expression constructs by Drs Florian Krammer and Benhur Lee, Icahn School of Medicine at Mount Sinai, New York, USA (Development of SARS-CoV-2 reagents was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C), and the protein production by Drs Paula Alves, Pedro Cruz, and Rute Castro at Instituto de Biologia Experimental e Tecnológica (iBET) Oeiras, Portugal as part of the Serology4COVID consortium. Publisher Copyright: © 2020 The Authors. European Journal of Immunology published by Wiley-VCH GmbH

PY - 2020/12

Y1 - 2020/12

N2 - SARS-CoV-2 has emerged as a human pathogen, causing clinical signs, from fever to pneumonia—COVID-19—but may remain mild or asymptomatic. To understand the continuing spread of the virus, to detect those who are and were infected, and to follow the immune response longitudinally, reliable and robust assays for SARS-CoV-2 detection and immunological monitoring are needed. We quantified IgM, IgG, and IgA antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) or the Spike (S) protein over a period of 6 months following COVID-19 onset. We report the detailed setup to monitor the humoral immune response from over 300 COVID-19 hospital patients and healthcare workers, 2500 University staff, and 198 post-COVID-19 volunteers. Anti-SARS-CoV-2 antibody responses follow a classic pattern with a rapid increase within the first three weeks after symptoms. Although titres reduce subsequently, the ability to detect anti-SARS-CoV-2 IgG antibodies remained robust with confirmed neutralization activity for up to 6 months in a large proportion of previously virus-positive screened subjects. Our work provides detailed information for the assays used, facilitating further and longitudinal analysis of protective immunity to SARS-CoV-2. Importantly, it highlights a continued level of circulating neutralising antibodies in most people with confirmed SARS-CoV-2.

AB - SARS-CoV-2 has emerged as a human pathogen, causing clinical signs, from fever to pneumonia—COVID-19—but may remain mild or asymptomatic. To understand the continuing spread of the virus, to detect those who are and were infected, and to follow the immune response longitudinally, reliable and robust assays for SARS-CoV-2 detection and immunological monitoring are needed. We quantified IgM, IgG, and IgA antibodies recognizing the SARS-CoV-2 receptor-binding domain (RBD) or the Spike (S) protein over a period of 6 months following COVID-19 onset. We report the detailed setup to monitor the humoral immune response from over 300 COVID-19 hospital patients and healthcare workers, 2500 University staff, and 198 post-COVID-19 volunteers. Anti-SARS-CoV-2 antibody responses follow a classic pattern with a rapid increase within the first three weeks after symptoms. Although titres reduce subsequently, the ability to detect anti-SARS-CoV-2 IgG antibodies remained robust with confirmed neutralization activity for up to 6 months in a large proportion of previously virus-positive screened subjects. Our work provides detailed information for the assays used, facilitating further and longitudinal analysis of protective immunity to SARS-CoV-2. Importantly, it highlights a continued level of circulating neutralising antibodies in most people with confirmed SARS-CoV-2.

KW - COVID-19

KW - Neutralizing antibodies

KW - SARS-CoV-2

KW - Seroprevalence

UR - https://www.scopus.com/pages/publications/85096933476

U2 - 10.1002/eji.202048970

DO - 10.1002/eji.202048970

M3 - Article

C2 - 33084029

AN - SCOPUS:85096933476

SN - 0014-2980

VL - 50

SP - 2025

EP - 2040

JO - European Journal of Immunology

JF - European Journal of Immunology

IS - 12

ER -

Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset

Resumo

ODS da ONU

Acesso ao documento

Outros arquivos e links

Impressão digital

Projetos

CIIS: Centro de Investigação Interdisciplinar em Saúde

Citação